Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential

Abstract: Idenalislisib is a first-in-class, oral, selective phosphatidylinositol 3-kinase δ inhibitor that offers a chemotherapy-free option for patients with relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Clinical trials in iNHL have evaluated idelalisib as monotherapy and as combination therapy with rituximab, bendamustine, and rituximab + bendamustine. When administered to heavily pretreated patients with R/R iNHL, idelalisib monotherapy or combination therapy showed durable antitumor activity accompanied by sustained or improved quality-of-life outcomes. Idenalislisib has an acceptable safety profile; however, serious or fatal diarrhea/colitis, hepatotoxicity, pneumonitis, and intestinal perforation have occurred in treated patients. Selective inhibition of phosphatidylinositol 3-kinase δ with idelalisib is a valuable addition to available treatment options for patients with iNHL, many of whom do not respond to or cannot tolerate chemoimmunotherapy. Two Phase III, randomized, placebo-controlled trials of idelalisib as combination therapy with rituximab or bendamustine + rituximab and a Phase I trial of idelalisib in combination with the Bruton’s tyrosine kinase inhibitor ONO/GS-4059 in R/R B-cell malignancies are currently ongoing. A Phase III monotherapy trial in previously treated follicular lymphoma or small lymphocytic lymphoma is planned. The development of other kinase inhibitors for the treatment of iNHL raises the potential for new treatment combinations. Additional research is needed to determine optimal therapy (monotherapy vs combination regimens), treatment sequencing, and long-term management.

Keywords: B-cell receptor, follicular lymphoma, elderly, targeted therapy, kinase inhibitor, phosphatidylinositol 3-kinase

Introduction

Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of solid tumors of the lymphatic system. Approximately 90% of NHLs arise from B lymphocytes. The National Cancer Institute estimated that in 2012, 549,625 people in the USA were living with NHL and that in 2015 there will be 71,850 new cases of NHL and 19,790 NHL-related deaths in the USA, which represents 4.3% of all new cases of cancer and 3.4% of all cancer-related deaths. Based on 2010–2012 data, the National Cancer Institute estimated that ~2.1% of men and women will be diagnosed with NHL during their lifetime.

Approximately one third of NHLs are indolent. Indolent NHLs (iNHLs) are slow-growing tumors with a prolonged natural history, and most patients present with advanced disease. iNHLs are highly treatable but rarely cured. Subtypes of iNHL include the most common form, follicular lymphoma (FL), marginal zone lymphoma (MZL), and small lymphocytic lymphoma (SLL), and the least common form, Waldenström macroglobulinemia (WM) or lymphoplasmacytic lymphoma.
Advanced disease, age >60–70 years, male sex, systemic symptoms, poor performance status, tumor burden, absence of interfollicular fibrosis, and cytogenetic abnormalities have been associated with poor prognosis in iNHL. In elderly patients (>90 years) with lymphoma, identified prognostic factors include high number of medications, anemia, and lymphopenia. The natural course of FL can vary widely. Over the last decade, there have been significant advances with respect to identifying prognostic markers that can be used to adequately stratify risk in patients with FL. The Follicular Lymphoma International Prognostic Index (FLIPI) includes patient’s age, Ann Arbor stage, hemoglobin level, number of nodal sites, and serum lactate dehydrogenase level. Although it is a widely accepted risk assessment tool, ~20% of patients with FL have early progression of disease (relapse within 2 years of initial chemoimmunotherapy), and these patients are at increased risk of poor outcomes (5-year overall survival [OS] rate of 50% vs 90% in patients without early progression of disease). Hence, FLIPI score may not be sufficient to identify this high-risk patient subset. Recently, it was demonstrated that integration of the mutational status of seven genes with the FLIPI clinical risk factors improves prognostication for patients with FL receiving first-line immunochemotherapy. This proposed clinicogenetic risk model (the m7-FLIPI) shows promise in identifying the subset of patients with the highest risk of treatment failure. High-risk patients with FL represent a highly important unmet need for both prognosis and treatment.

Nevertheless, iNHL is most often diagnosed in older individuals. The median age at diagnosis ranges from 65 years for FL to 72 years for MZL, and the incidence rates increase dramatically with age. Thus, the growth of the elderly population has likely contributed to the increased rate of NHL diagnoses over time. Elderly patients with iNHL have high rates of medical comorbidities, such as cardiovascular disease, hypertension, and vascular and respiratory tract disorders, which may limit their ability to tolerate certain myelosuppressive regimens. Retrospective analysis of 133 patients aged ≥80 years with iNHL showed that 74% had a Cumulative Illness Rating Scale – Geriatric score of ≥6. However, lymphoma is the main cause of death in elderly patients with iNHL, necessitating treatments that combine efficacy with tolerability in a frail patient population.

**Current treatment approaches in iNHL**

Though iNHLs remain incurable, treatment is markedly advanced after the advent of the anti-CD20 monoclonal antibody rituximab, which now has widespread use both as monotherapy and in chemoimmunotherapy regimens for first-line and relapsed or refractory (R/R) diseases. Recommended first-line regimens for grade 1–2 FL include rituximab monotherapy; rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP); rituximab, cyclophosphamide, vincristine, prednisone (RCVP); and rituximab in combination with bendamustine or lenalidomide. Recommended second-line and subsequent therapies, in order of preference, are chemoimmunotherapy (same options recommended for first-line treatment), rituximab, lenalidomide ± rituximab, radioimmunotherapy,idelisib, fludarabine + rituximab, and rituximab + fludarabine + mitoxantrone + dexamethasone.

Findings from an early trial of rituximab monotherapy in 62 patients with previously untreated iNHL (FL or SLL) demonstrated that 4 weekly infusions of 375 mg/m² resulted in an objective response rate (ORR) of 47% at 6 weeks; 45% of patients had stable disease, and 8% had tumor progression at that time point. When the patients with stable disease continued maintenance therapy with the same rituximab regimen administered every 6 months, 73% achieved ORR and 37% achieved a complete response (CR). A compelling body of evidence from randomized controlled trials demonstrates that chemoimmunotherapy with rituximab improves outcomes compared with chemotherapy alone in patients with newly diagnosed or relapsed iNHL. In a randomized trial in patients with previously untreated advanced-stage FL, R-CHOP significantly improved the ORR, OS, and duration of response (DOR) compared with patients randomized to CHOP. In a 9-year follow-up study of a Phase II trial of open-label R-CHOP in treatment-naive or previously treated patients with low-grade FL, the median time to progression and DOR were ~7 years. Similarly, RCVP has been demonstrated to improve the ORR and OS and extend the time to progression compared with cyclophosphamide, vincristine, and prednisone in patients with previously untreated FL. The combination of bendamustine + rituximab (BR) was more effective than R-CHOP as first-line treatment in patients with iNHL or mantle cell lymphoma and was associated with fewer serious adverse events (AEs; 19% for BR vs 29% for R-CHOP).

With advances in treatment, NHL death rates have declined; between 2007 and 2011, rates decreased by 1.8% per year for men and 2.9% per year for women, despite a slight increase in NHL incidence rates in men (0.3%/year). Although the increased response rates and prolonged progression-free survival (PFS) with rituximab monotherapy and combination therapy are encouraging, as noted earlier, ~20% of patients relapse within 2 years.
of first-line chemoimmunotherapy,24,25 and these patients have lower survival rates compared with patients who did not relapse in the first 2 years (OS at 2 years, 68% vs 97%, respectively).11 Moreover, responses to second-line therapies are often suboptimal, suggesting that salvage regimens are poorly effective after first-line rituximab.26

An analysis of data from the National LymphoCare Study revealed that patients older than 80 years were most likely to be treated with first-line rituximab monotherapy or observation only instead of chemoimmunotherapy, and when combination therapy was used, it was generally RCVP.27 Although current practice supports the use of rituximab-based regimens in younger, medically fit patients, rituximab monotherapy or watchful waiting is generally recommended for elderly or frail patients.28 In the National Comprehensive Cancer Network guidelines, recommendations for first-line therapy in the elderly or infirm are limited to rituximab monotherapy, single-agent alkylators, and radioimmunotherapy.15 Taken together, it is clear that there is a substantial unmet need for effective, well-tolerated treatments in R/R patients and elderly or frail patients with iNHL.

**Idelalisib: a targeted approach to the treatment of iNHL**

The phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that play an important role in signal transduction and membrane trafficking and are frequently dysregulated in cancers.29,30 The class 1 PI3Ks participate in catalytic and regulatory signal transduction and membrane trafficking events. In humans, the PI3K pathway plays an important role in B-cell development, proliferation, migration, adhesion, survival, and immune functions.31 Dysregulation of the PI3K pathway seems to confer survival and retention in some malignant B cells.31 The PI3Kδ isoform is selectively expressed in leukocytes, making it a desirable therapeutic target for B-cell malignancies.29

Idelalisib (Zydeliga®) is a first-in-class, oral, selective, PI3Kδ inhibitor.32 In vitro studies have demonstrated that idelalisib potently and selectively inhibits PI3Kδ signaling33 and induces apoptosis in patient-derived malignant B cells.34 In the USA, idelalisib is approved for the treatment of relapsed FL and relapsed SLL in patients who have received at least two prior systemic therapies and for the treatment of relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy because of other comorbidities.35 In Europe, idelalisib is approved as monotherapy for adults with refractory FL and in combination with rituximab for adults with CLL.36 Idelalisib represents a rational treatment option for patients who are not ideal candidates for standard chemotherapy. The high degree of leukocyte selectivity of idelalisib forms the basis for its clinical activity and acceptable toxicity profile.

**Clinical efficacy of idelalisib in iNHL**

The NCCN Clinical Practice Guidelines in Oncology include idelalisib as a recommended treatment option in second-line or subsequent therapy in patients with grade 1–2 FL, making it one of the few alternative treatments available for patients with iNHL that is refractory to rituximab or alkylating agents.15 The efficacy of idelalisib monotherapy was first reported in a Phase I dose-ranging study of 64 patients with previously treated iNHL (FL, n=38; SLL, n=11; MZL, n=6; lymphoplasmacytic lymphoma, n=9; Table 1).37 The patients had received a median of 4 (range: 1–10) prior therapies; >90% had previously received rituximab or an alkylating

**Table I Efficacy of idelalisib in clinical trials in iNHL**

<table>
<thead>
<tr>
<th>Study</th>
<th>Regimen</th>
<th>Population</th>
<th>Efficacy results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I dose-ranging study27</td>
<td>IDELA 50–350 mg QD or BID continuously or intermittently (3 weeks on, 1 week off)</td>
<td>N=64 R/R iNHL; 97% had rituximab as prior therapy</td>
<td>ORR, 47%; TTR, 1.3 mo; DOR, 18.4 mo; PFS, 7.6 mo</td>
</tr>
<tr>
<td>Phase I combination therapy study38</td>
<td>IDELA 150 mg BID + rituximab, B, or both</td>
<td>N=79 R/R iNHL; 58% were refractory to rituximab</td>
<td>ORR, 81%; CR, 33%; ORR for IDELA + R (75%), IDELA + B (88%), and IDELA + R + B (79%); DOR for IDELA + R (28.6 mo); not reached for IDELA + B or IDELA + R + B</td>
</tr>
<tr>
<td>Phase II monotherapy study4</td>
<td>IDELA 150 mg BID monotherapy</td>
<td>N=125 iNHL refractory to rituximab and an alkylating agent</td>
<td>ORR, 57%; TTR, 1.9 mo; DOR, 12.5 mo; PFS, 11 mo</td>
</tr>
</tbody>
</table>

**Abbreviations:** B, bendamustine; BID, twice daily; CR, complete response; DOR, duration of response; IDELA, idelalisib; iNHL, indolent non-Hodgkin lymphoma; mo, months; ORR, objective response rate; PFS, progression-free survival; QD, once daily; R, rituximab; R/R, relapsed or refractory; TTR, time to response.
agent, and 58% were refractory to the last prior therapy. Idelalisib dose ranging consisted of continuous regimens of 50–350 mg once or twice daily or an intermittent regimen of 150 mg twice daily (3 weeks on, 1 week off every 4 weeks). Nineteen patients (30%) completed the initial 48-week study and entered an extension phase. The mean treatment duration was 9.3 months, and the maximum tolerated dose was not identified at study end point. The ORR was 47% (n=30) in the total study population and 59% in patients treated with continuous higher doses. Responding patients had a rapid reduction in lymphadenopathy with a median time to response of 1.3 months (range: 0.7–14). The median (range) DOR and PFS were 18.4 (0.03–34) months and 7.6 (0.03–37) months, respectively. Because the median PFS was longer in patients treated with higher dose continuous therapy (16.8 months; range: 1–37 months) than in patients receiving lower doses or intermittent therapy (3.7 months; range: 0.5–33 months), idelalisib doses of ≥150 mg twice daily were identified for further study.

Idelalisib + rituximab or bendamustine or both were evaluated in a Phase I study of 79 patients with R/R iNHL (Table 1). The patients had received a median of 3 (range: 1–11) prior courses of therapy. Most patients had been treated with rituximab (98%) or an alkylating agent (86%), and 58% were refractory to rituximab. The first eight patients in each group received idelalisib 100 mg twice daily; thereafter, patients were treated with 150 mg twice daily. Rituximab was administered as a 375 mg/m² infusion once weekly for eight doses, and the bendamustine dose was 90 mg/m² administered on days 1 and 2 of each cycle for six cycles. The ORR was 81%, and 33% of patients achieved a CR. The ORRs for the idelalisib + rituximab, idelalisib + bendamustine, and idelalisib + BR groups were 75%, 88%, and 79%, respectively. The median DOR for idelalisib + rituximab–treated patients was 28.6 months, but at the time these data were presented, the DOR had not yet been reached for the other treatment groups. A durable response of over 2 years supported further evaluation of idelalisib combination regimens in Phase III studies.

Based on the promising results from the Phase I studies, a Phase II trial of idelalisib monotherapy (150 mg twice daily) was conducted in 125 heavily pretreated patients with relapsed iNHL (Table 1). The patients had received a median of 4 (range: 2–12) prior treatment courses; 100% were refractory to rituximab, 99% to alkylating agents, and 75% to bendamustine. FL was the most common subtype (58%), and 17% of patients with FL had grade 3A disease. With a median duration of idelalisib treatment of 6.6 months (range: 0.6–23.9 months), the ORR was 57% (n=71) and responses were rapid (median time to response, 1.9 months [range: 1.6–8.3 months]) and durable (median DOR, 12.5 months [range: 0.03–14.8 months]). The ORR was similar in subgroups stratified by age (57% in patients aged <65 years and ≥65 years), presence of bulky disease (no [57%] vs yes [58%]), number of previous therapies (<4 [50%] and ≥4 [62%]), refractoriness to last prior therapy (no [69%] vs yes [55%]), and refractoriness to bendamustine (no [50%] vs yes [59%]). The median (range) PFS was 11.0 (0.03–16.6) months, and at data cutoff, the median (range) OS was 20.3 (0.7–22.0) months.

Patients in this study demonstrated clinically meaningful improvements in health-related quality-of-life metrics, including lymphoma-related concerns, based on the Functional Assessment of Cancer Therapy – Lymphoma. A decision-analysis model that extracted survival data and compared them with health outcomes data from a claims analysis database showed that idelalisib therapy was associated with benefits in life-years gained (7.8 months), progression-free life-years gained (4.6 months), and quality-adjusted life-years gained (0.5 year).

A subsequent subgroup analysis evaluated idelalisib efficacy and safety in patients with FL (n=72) enrolled in the Phase II trial, with a median (range) treatment duration of 6.5 (0.6–31.0) months and median (range) follow-up of 19.4 (0.7–35.6) months. In these R/R patients with FL (54% had a high FLIPI risk score at baseline; 79% were refractory to at least two regimens; 17% had FL grade 3A), the ORR was 55.6% and median (range) PFS was 11.0 (0–30.6) months versus 5.1 (4.4–6.0) months with the last prior therapy. The median OS was not reached, and OS rates at 12 months, 18 months, and 24 months were 88.1%, 74.2%, and 69.8%, respectively. These data suggest that patients with high-risk FL may benefit from a targeted therapy such as idelalisib.

**Safety and tolerability in iNHL**

Idelalisib exhibited an acceptable safety profile in patients treated for up to 4 years in the Phase I and II trials. In the Phase II trial, the most frequent AEs (≥20%) were diarrhea (43%), nausea (30%), fatigue (30%), cough (29%), and pyrexia (28%). Twenty-five patients discontinued because of AEs, including elevated liver transaminases, pneumonia/pneumonitis, diarrhea, colitis, and neutropenia. Grade ≥3 treatment-emergent AEs occurring in >2% of patients were diarrhea (13%), pneumonia (7%), and dyspnea (3%). Increased bleeding or bruising was not reported. Grade ≥3
diarrhea and/or colitis occurred in 16% of patients, with a median onset of 6 months; six cases resolved spontaneously or after dose reduction and eight cases resolved with temporary interruption of therapy. Idelalisib was permanently discontinued in six patients with grade ≥3 diarrhea. Laboratory abnormalities occurring in ≥10% of patients included neutropenia (any grade, 56%; grade ≥3, 27%), alanine aminotransferase (ALT) elevation (any grade, 47%; grade ≥3, 13%), aspartate aminotransferase (AST) elevation (any grade, 35%; grade ≥3, 8%), anemia (any grade, 28%; grade ≥3, 2%), thrombocytopenia (any grade, 26%; grade ≥3, 6%), alkaline phosphatase elevation (any grade, 22%; grade ≥3, 0%), and bilirubin elevation (any grade, 10%; grade ≥3, 0%). The median onset for grade ≥3 liver transaminase elevations was 6.3 weeks after starting idelalisib (n=16); all such events were reversible, with a median onset of resolution to grade ≤1 of 3.9 weeks.

Idelalisib prescribing information includes a black box warning for fatal and severe hepatotoxicity, diarrhea or colitis, pneumonitis, and intestinal perforation. Based on anecdotal effectiveness, the panel recommended that once infectious source has been ruled out, budesonide or antidiarrheal medications. Diarrhea typically has a late onset (after 2 months) and can occur several months after idelalisib initiation; hence, it is important to remind patients to alert their medical providers of any diarrhea lasting >24 hours.

**Future considerations**

There are currently six ongoing clinical studies of idelalisib in iNHL registered on the ClinicalTrials.gov web site (Table 2). These include two Phase III trials evaluating idelalisib in combination with rituximab (NCT01732913; Yosemite) and in combination with BR (NCT01732926; Bridalveil) in previously treated patients with iNHL. The Yosemite trial began enrolling patients in January 2013 and is expected to be completed in June 2022 (primary data collection will be completed in June 2019). The Bridalveil trial began in January 2013 with a planned completion date of September 2022 (September 2017 for completion of primary data collection). A third Phase III trial is evaluating the effectiveness and safety of idelalisib monotherapy in previously treated FL or SLL (NCT02536300), and a Phase II trial is evaluating the effectiveness and safety of idelalisib in previously treated WM (NCT02439138). Also currently ongoing are a Phase I trial evaluating the treatment combination of idelalisib with the investigational Bruton’s tyrosine kinase (BTK) inhibitor ONO/GS-4059 (NCT02457598) in R/R patients and a Phase I/II trial of idelalisib monotherapy in previously treated iNHL (NCT01306643).

Clinical trials are needed to evaluate the role of idelalisib as the first-line therapy in iNHL, address the sequencing of idelalisib with respect to chemotherapy, and determine optimal combination regimens. At present, idelalisib is

Table 2  Ongoing or planned idelalisib trials in iNHL

<table>
<thead>
<tr>
<th>Study</th>
<th>Regimen</th>
<th>Population</th>
<th>Target accrual (status/primary end point(s))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I (NCT02457598)</td>
<td>Idelalisib + ONO/GS-4059; open label</td>
<td>Relapsed or refractory B-cell malignancies</td>
<td>N=138 (recruiting) Safety, toxicity, ORR</td>
</tr>
<tr>
<td>Phase II (NCT01306643)</td>
<td>Idelalisib monotherapy; open label</td>
<td>Previously treated iNHL</td>
<td>N=15 (recruiting) Safety, response rate</td>
</tr>
<tr>
<td>Phase II (NCT02439138)</td>
<td>Idelalisib monotherapy; open label</td>
<td>Previously treated Waldenstrom macroglobulinemia</td>
<td>N=30 (recruiting) ORR</td>
</tr>
<tr>
<td>Phase III (NCT01732913; Yosemite)</td>
<td>Idelalisib + rituximab; placebo controlled</td>
<td>Previously treated iNHL</td>
<td>N=375 (recruiting) PFS, response rate, OS</td>
</tr>
<tr>
<td>Phase III (NCT01732926; Bridalveil)</td>
<td>Idelalisib + bendamustine + rituximab; placebo controlled</td>
<td>Previously treated iNHL</td>
<td>N=450 (recruiting) PFS</td>
</tr>
<tr>
<td>Phase III (NCT02536300)</td>
<td>Idelalisib monotherapy</td>
<td>Previously treated follicular lymphoma or small lymphocytic lymphoma</td>
<td>N=240 (recruiting) Safety, ORR</td>
</tr>
</tbody>
</table>

**Abbreviations:** iNHL, indolent non-Hodgkin lymphoma; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.
approved in the USA for the management of relapsed FL or SLL in patients who have received at least two prior systemic therapies. In fit patients, there are no data to guide clinicians in deciding between initiating chemotherapy, which can cause myelosuppression and other complications, or initiating a targeted therapy such as idelalisib that could avoid myelosuppressive complications. The limited data available on idelalisib as frontline therapy in CLL (a different B-cell lymphoproliferative disorder) seem to suggest that it may be associated with an increased risk of severe immune-mediated toxicities in this setting. There were high rates of severe toxicities in patients with CLL receiving frontline therapy with idelalisib + ofatumumab (grade ≥3 toxicity, 76%) or idelalisib + rituximab (grade ≥3 toxicity, 89%). The most common grade ≥3 toxicities were ALT/AST elevation (57%), enterocolitis (14%), and pneumonitis (10%) in the idelalisib + ofatumumab study and diarrhea or colitis (42%) and pneumonia (19%) in the idelalisib + rituximab study. In addition to further clinical trials, preclinical studies may be useful to identify the mechanisms for such toxicity and markers for selecting patients who tolerate frontline idelalisib well.

Additional unanswered questions relate to long-term outcomes on continued idelalisib therapy. Current practice is to continue idelalisib treatment until disease progression or the occurrence of unacceptable toxicity, but little is known about whether treatment can be safely discontinued in patients who have achieved a clinical end point. Moreover, to guide treatment in patients who stop responding to idelalisib, clinical and preclinical data are needed to elucidate idelalisib resistance and to identify effective salvage therapy, which could involve treatment add-on or switching to a different targeted agent. The possible benefit of idelalisib beyond disease progression is not known because all clinical trials conducted to date have excluded patients who demonstrated disease progression while on therapy.

The development and clinical investigation of other targeted therapies create the potential for many novel idelalisib treatment combinations for iNHL. In addition to the BTK inhibitor ibrutinib (Imbruvica), which is approved for use in MCL, CLL, and WM, a number of other kinase inhibitors are currently in development (Table 3). These include the PI3Kδ inhibitors TGR-1202 and AMG 319, the PI3Kγ inhibitor duvelisib (IPI-145), the PI3Kδ inhibitor copanlisib (BAY 80-6946), and the B-cell lymphoma-2 inhibitor venetoclax (ABT-199). Duvelisib and copanlisib are currently in Phase III development in FL and NHL, respectively. A Phase II study of duvelisib monotherapy in 32 patients with R/R iNHL demonstrated clinical activity at doses of 15 mg twice daily to 75 mg twice daily with an ORR of 65%, including five CRs, 14 partial responses, and one minor response. The most common grade ≥3 AEs were ALT/AST increase (41%) and diarrhea (22%) and grade ≥3 neutropenia was reported in 31% of patients. In a Phase IIA study in 33 patients with R/R iNHL or CLL, copanlisib monotherapy produced an ORR of 47%, with one CR, one unconfirmed CR, and 13 partial responses. The most common grade ≥3 AEs were hypertension (49%), neutropenia (30%), hyperglycemia (30%), and anemia (15%). Two second-generation BTK inhibitors, ONO-4059 (Phase I) and acalabrutinib (ACP-196; Phase I/II), are currently in development.

With the abundance of potential combination therapies, it is important to determine in a clinical trial setting whether such strategies can improve outcomes without increasing toxicity compared with idelalisib monotherapy. A Phase II clinical trial of idelalisib in combination with the spleen tyrosine kinase inhibitor entospletinib in R/R CLL or NHL was discontinued due to frequent occurrence of pneumonitis (NCT01796470). Two trials evaluating idelalisib + lenalidomide in recurrent FL (NCT01644799) and lenalidomide ± idelalisib in mantle cell lymphoma (NCT01838434) were suspended owing to tumor flares in treated patients. Moreover, the triplet of idelalisib + lenalidomide + rituximab has been associated with unexpected and serious toxicities, including rash, fevers, hypotension, and hepatotoxicity, which were thought to be related to high-level immune activation. In contrast, results of a prespecified interim analysis of a Phase III, randomized, double-blind trial comparing idelalisib + BR with placebo + BR in patients with R/R CLL show superior PFS (primary end point) and OS (secondary end point) in the idelalisib versus placebo arm, without increased toxicity compared with previous studies. However, that study did not address whether the addition of bendamustine adds substantially to the backbone of idelalisib and rituximab.

### Table 3 Novel targeted therapies in development for iNHL

<table>
<thead>
<tr>
<th>Agent (development phase in iNHL)</th>
<th>Therapeutic target</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGR-1202 (Phase I)</td>
<td>PI3Kδ</td>
</tr>
<tr>
<td>AMG 319 (Phase I)</td>
<td>PI3Kδ</td>
</tr>
<tr>
<td>IPI-145/duvelisib (Phase III)</td>
<td>PI3Kδ and PI3Kγ</td>
</tr>
<tr>
<td>BAY 80-6946/copanlisib (Phase III)</td>
<td>PI3Kζ and PI3Kδ</td>
</tr>
<tr>
<td>ABT-199/venetoclax (Phase II)</td>
<td>BCL-2</td>
</tr>
<tr>
<td>ONO/GS-4059 (Phase I)</td>
<td>BTK</td>
</tr>
<tr>
<td>ACP-196/acalabrutinib (Phase I/II)</td>
<td>BTK</td>
</tr>
</tbody>
</table>

Abbreviations: BCL-2, B-cell lymphoma 2; BTK, Bruton’s tyrosine kinase; iNHL, indolent non-Hodgkin lymphoma; PI3K, phosphatidylinositol 3-kinase.
monotherapy in CLL. It is for this reason that well-designed clinical trials are essential to identify effective treatment strategies that can improve response and remission duration while maintaining an acceptable toxicity profile.

**Conclusion**

The iNHLs are a heterogeneous group of malignancies that are treatable but not curable. The anti-CD20 antibody rituximab has been the mainstay of first- and second-line treatments of iNHL as monotherapy or chemoimmunotherapy. Unfortunately, initial reductions in tumor burden following rituximab therapy often are not sustained, and response rates decline with repeated courses. Patients with iNHL often endure multiple courses of chemoimmunotherapy that increase the risk of serious cardiac toxicity and myelosuppression. This is particularly problematic in elderly patients with iNHL.

Selective inhibition of the PI3Kδ pathway with oral idelalisib represents a viable and clinically useful chemotherapy-free option for patients with iNHL. Clinical trial data demonstrate the effectiveness of idelalisib as monotherapy or combination therapy in patients with R/R iNHL and as monotherapy in high-risk FL, with an acceptable AE profile. Ongoing trials will provide additional Phase III data and inform new treatment combinations. An important objective for future research is to determine whether combination therapies can succeed in improving outcomes over monotherapy without increasing toxicity.

**Acknowledgments**

Jacqueline C Barrientos’ work is supported in part by the National Institutes of Health/National Center for Advancing Translational Sciences Grant UL1TR00457, the 2015 American Society of Hematology–Harold Amos Medical Faculty Development Program fellowship, and philanthropic contributions from the Nash Family Foundation, Karches Family Foundation, Jerome Levy Foundation, Leon Levy Foundation, and Frank and Mildred Feinberg Foundation. Editorial assistance for the development of this manuscript was provided by Sally Laden, MS, a medical writer at C4 MedSolutions, LLC (Yardley, PA, USA), a CHC Group company, who received funding from Gilead Sciences, Inc. Gilead did not contribute to, review, edit, or comment on the paper.

**Disclosure**

Dr Barrientos reports the following disclosures: institutional research funding from Gilead and AbbVie and advisory board consulting for Gilead, AbbVie, Jannsen, and Genentech. The author reports no other conflicts of interest in this work.

**References**


